Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment

NCT01320111 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Paclitaxel and Sorafenib
DRUG: Paclitaxel

Sponsor

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Collaborators

[object Object]